Clinical trials: Hypothalamic Diseases
Cushing Syndrome
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may…
- Trial name
- NCT03604198
- Testing
- relacorilant
- Where
- 48 sites in United States, Austria and 8 more
- Volunteers
- 125 people
- Sponsor
- Corcept Therapeutics
Pituitary Adenoma, Adrenal Insufficiency
Hydrocortisone Use During Peri-operation for Pituitary Adenomas
The investigators hypothesize that withholding hydrocortisone during the peri-operation in patients with pituitary adenomas whose hypothalamus pituitary adrenal axis are intact are safe.
- Conditions
- Pituitary Adenoma, Adrenal Insufficiency, Surgery
- Trial name
- NCT04621565
- Testing
- Normal saline, Hydrocortisone
- Where
- China
- Volunteers
- 436 people
- Sponsor
- Peking Union Medical College Hospital
Acromegaly
An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly
Acromegaly is a rare, serious condition characterized by chronic hypersecretion of growth hormone (GH), generally caused by a GH-secreting pituitary adenoma.
- Trial name
- NCT00171730
- Testing
- Pasireotide
- Where
- 10 sites in United States, Australia and 5 more
- Volunteers
- 30 people
- Sponsor
- Novartis Pharmaceuticals
Childhood Soft Tissue Sarcoma, Childhood Liver Cancer
Liposomal Doxorubicin in Treating Children With Refractory Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: Phase I trial to study the effectiveness of liposomal doxorubicin in treating children who have…
- Conditions
- Childhood Soft Tissue Sarcoma, Childhood Liver Cancer, Bone Cancer, Brain Tumor
- Trial name
- NCT00019630
- Testing
- doxorubicin HCl liposome
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Brain Neoplasm, Glioblastoma
Evaluation of Factors in Human Brain Tumors
Presently, patients with primary malignant brain tumors have a life expectancy of 15 weeks following surgery unless they receive additional types of therapy (chemotherapy, radiotherapy, and/or immunotherapy).
- Conditions
- Brain Neoplasm, Glioblastoma, Glioma, Pituitary Neoplasm
- Trial name
- NCT00001171
- Where
- United States
- Volunteers
- 800 people
- Sponsor
- National Institute of Neurological Disorders and Stroke (NINDS)
Acromegaly
Somatostatin Analogues in the Treatment of Relapsing GH Pituitary Adenomas After Surgery
At present there are no recommendations regarding the possibility of discontinuing treatment in cases of recurrent acromegaly with good hormonal control.
- Trial name
- STOP-SST (NCT05149495)
- Where
- France
- Volunteers
- 100 people
- Sponsor
- University Hospital, Strasbourg, France
Growth Hormone Deficiency
Differential Effects of rhGH vs. rhIGF-1 on Cardiovascular Risk Factors
The purpose of this study is to see if giving growth hormone or insulin-like growth factor-1 (IGF-1) to subjects with growth hormone deficiency effects cardiovascular risk factors differently.
- Trial name
- NCT00684957
- Testing
- Recombinant Human Growth Hormone, Recombinant Human IGF-1
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Columbia University
Growth Hormone Deficiency, Cardiovascular Diseases
GH and Cardiovascular Risk Factors
Rationale: Abnormally low and high levels of insulin-like growth factor-I (IGF-I) are both associated with increased metabolic risk.
- Conditions
- Growth Hormone Deficiency, Cardiovascular Diseases, Metabolic Syndrome, Cognition
- Trial name
- NCT01877512
- Testing
- Change in daily dosage of Growth Hormone
- Where
- Netherlands
- Volunteers
- 32 people
- Sponsor
- Amsterdam UMC, location VUmc
Growth Hormone Deficiency Without Epiphyseal Closure
Ngenla Subcutaneous Injection Special Investigation
The purpose of this study is to learn about the long-term safety and effects of Ngenla. Ngenla is approved for treatment of GHD (Growth hormone deficiency) without epiphyseal closure under daily medical practice.
- Trial name
- NCT05602766
- Testing
- NGENLA (Somatrogon)
- Where
- Japan
- Volunteers
- 1 people
- Sponsor
- Pfizer
Pituitary Tumor
Postoperative Cognitive Dysfunction in Patients Undergoing Pituitary Removal Surgery
As postoperative cognitive dysfunction rates are high especially in elder patients, cognitive dysfunction is not diagnosed and treated effectively.
- Trial name
- NCT03719781
- Testing
- standardized minimental testing
- Where
- Turkey (Türkiye)
- Volunteers
- 90 people
- Sponsor
- Kocaeli University
Cavernous Sinus Meningioma, Pituitary Adenoma
Effect of Irradiation of the Cavernous Sinus and the Sellar Region on Autobiographical Memory
Several studies showed that radiotherapy as brain tumors treatment may affect cognition. It was observed that durable memory impairments could arise at irradiated patients if radiotherapy is applied on medial temporal lobes.
- Trial name
- ISOMAB (NCT02750371)
- Testing
- Evaluation of autobiographical memory
- Where
- France
- Volunteers
- 17 people
- Sponsor
- University Hospital, Bordeaux
Acromegaly
An Open-label, Multi-center, Expanded Treatment Protocol of Pasireotide LAR in Patients With Acromegaly
The present study is planned as an expanded treatment protocol to provide acromegalic patients for whom medical therapy is appropriate access to pasireotide LAR while regulatory approval for pasireotide is sought.
- Trial name
- ACCESS (NCT01995734)
- Testing
- Pasireotide long acting release formulation
- Where
- 37 sites in United States
- Sponsor
- Novartis Pharmaceuticals
Hyponatremia, Dilutional Hyponatremia
Effects of Tolvaptan vs Fluid Restriction in Hospitalized Subjects With Dilutional Hyponatremia
The purpose of this study is to determine if hospitalized patients with symptomatic hyponatremia treated with tolvaptan are in the hospital for less time than patients treated with fluid restriction.
- Conditions
- Hyponatremia, Dilutional Hyponatremia, Inappropriate ADH Syndrome
- Trial name
- SALACIA (NCT01227512)
- Testing
- tolvaptan, Fluid Restriction
- Where
- 56 sites in United States
- Volunteers
- 124 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
Metabolism, Insulin Resistance
The Effect of Pharmacological Antilipolysis on the Metabolic Effects of Ghrelin
This study will investigate the non-growth-hormone-dependent metabolic effects of the hormone Ghrelin in growth hormone deficient subjects by examining the insulin tolerance as well as signal proteins in fat and muscle biopsies.
- Conditions
- Metabolism, Insulin Resistance, Hypopituitarism
- Trial name
- NCT01209416
- Testing
- Acipimox, Ghrelin
- Where
- Denmark
- Volunteers
- 8 people
- Sponsor
- University of Aarhus
Grade I Meningioma, Grade II Meningioma
Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
This phase II trial studies how well hypofractionated proton or photon radiation therapy works in treating patients with brain tumors.
- Conditions
- Grade I Meningioma, Grade II Meningioma, Grade III Meningioma, Intracranial Neoplasm
- Trial name
- HiPPI (NCT04278118)
- Testing
- Hypofractionated Radiation Therapy, Photon Beam Radiation Therapy, Proton Beam Radiation Therapy
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Emory University
Schizophrenia, Antipyretics Toxicity
Prolactin Change in Chinese Patients With Schizophrenia After Antipsychotics Treatment
Objective: Hyperprolactinemia(HPRL) which can result in a series of prolactin-related symptoms is a frequent adverse effect of antipsychotics.
- Conditions
- Schizophrenia, Antipyretics Toxicity, Prolactin Excess
- Trial name
- NCT04002258
- Testing
- Antipsychotic
- Where
- China
- Volunteers
- 10,363 people
- Sponsor
- Shanghai Mental Health Center
Prolactinoma, Pituitary Tumor
The PROMISE Survey
The PROMISE Survey was developed to systematically assess the real-world experiences, treatment preferences, side effects, and outcomes from both patients and physicians dealing with prolactinomas.
- Trial name
- NCT06936813
- Where
- Switzerland
- Volunteers
- 530 people
- Sponsor
- University Hospital, Basel, Switzerland
Cushing's Disease, Hypercortisolism
Osilodrostat Therapy and 11C-methionine PET to Improve Corticotroph Adenoma Detection
Cushing's disease is a rare condition where the body produces too much of a hormone called cortisol. Cortisol helps with metabolism, the immune system, and managing stress.
- Conditions
- Cushing's Disease, Hypercortisolism, Pituitary Adenoma, Pituitary ACTH Secreting Adenoma
- Trial name
- OPTIMAL (NCT06701838)
- Testing
- 11C-Methionine PET/CT
- Volunteers
- 15 people
- Sponsor
- Imperial College London
Acromegaly
A Prospective Study of Outcome After Therapy for Acromegaly
The purpose of this study is to evaluate hormone values and other markers of disease activity in a cohort of patients with acromegaly at the time of diagnosis and then prospectively after surgical or other treatment.
- Trial name
- NCT01809808
- Testing
- Surgery for acromegaly, Medications for acromegaly, Total body magnetic resonance imaging
- Where
- United States
- Volunteers
- 280 people, healthy volunteers welcome
- Sponsor
- Columbia University
Pituitary Tumour
Silastic Stent Study
Endoscopic skull base surgery is a relatively new procedure that is now a standard of care for surgeries at the base of the skull; however there are no studies that examine the healing process of the nasal lining with the use of…
- Trial name
- NCT03282058
- Testing
- Silastic Stent
- Volunteers
- 26 people
- Sponsor
- University of British Columbia